Improvement of solubility and dissolution rate of indomethacin by solid dispersions in Gelucire 50/13 and PEG4000

Saudi Pharmaceutical Journal

Volumn 17, Issue 3, 2009, Pages 217-225

  El Badry, Mahmoud ^a   Fetih, Gihan ^b   Fathy, Mohamed ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b University of Assiut   (Egypt)

Author keywords

Dissolution rate; Gelucire; Indomethacin; Solid dispersion; Solubility

Indexed keywords

CRYSTALLIN; GELUCIRE; INDOMETACIN; MACROGOL 4000;

ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DISSOLUTION; DRUG SOLUBILITY; MELTING POINT; SCANNING ELECTRON MICROSCOPY; SOLID; THERMOGRAPHY; X RAY POWDER DIFFRACTION;

EID: 72249095155     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2009.08.006     Document Type: Article

References (41)

1. Abdul-Fattah A.M., and Bhargava H.N. Preparation and in vitro evaluation of solid dispersions of halofantrine. Int. J. Pharm. 235 (2002) 17-33
2. Ahuja N., Katare O.P., and Singh B. Studies on dissolution enhancement and mathematical modelling of drug release of a poorly water-soluble drug using water soluble carriers. Eur. J. Pharm. Biopharm. 65 (2007) 26-38
3. Aïnaoui A., and Vergnaud J.M. Modeling the plasma drug level with oral sustained release forms with lipidic gelucire. Int. J. Pharm. 169 (1998) 155-162
4. Aïnaoui A., Ouriemchi E.M., Bidah D., El-Amrani M.K., and Vergnaud J.M. Process of drug release with oral dosage forms with lipidic gelucire matrix. J. Polym. Eng. 17 (1997) 245-257
5. Allahham A., and Stewart P.J. Enhancement of the dissolution of indomethacin in interactive mixtures using added fine lactose. Eur. J. Pharm. Biopharm. 67 (2007) 732-742
6. Alsaidan S.M., Alsughayer A.A., and Eshra A.G. Improved dissolution rate of indomethacin by adsorbents. Drug Dev. Ind. Pharm. 24 (1998) 389-394
7. Bandi N., Wei W., Roberts C.B., Kotra L.P., and Kompella U.B. Preparation of budesonide and indomethacin-hydroxy-propyl-beta-cyclodextrin (HPBCD) complexes using a single-step, organic-solvent-free supercritical fluid process. Eur. J. Pharm. Sci. 23 (2004) 159-168
8. Bogdanova S., Bontcheva E., and Avramova N. Phase characterization of indomethacin in adsorbates onto hydroxyl-ethylcellulose. Drug Dev. Ind. Pharm. 33 (2007) 900-906
9. Cavallari C., Rodriguez L., Albertini B., Passe-rini N., Rosetti F., and Fini A. Thermal and fractal analysis of diclofenac/Gelucire 50/13 microparticles obtained by ultra-sound-assisted atomization. J. Pharm. Sci. 94 (2005) 1124-1134
10. Cavallari C., Luppi B., Di Pietra A.M., Rodriguez L., and Fini A. Enhanced release of indomethacin from Pvp/stearic acid microcapsules prepared coupling Co-freeze-drying and ultrasound assisted spray-congealing process. Pharm. Res. 24 (2007) 521-529
11. Chiou W.L., and Riegelman S. Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 60 (1971) 1281-1302
12. Craig D.Q.M. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int. J. Pharm. 231 (2002) 131-144
13. Dennis A.B., Farr S.J., Kellaway I.W., Taylor G., and Davidson R. In vivo evaluation of rapid release and sustained release gelucire capsule formulation. Int. J. Pharm. 65 (1990) 85-100
14. Douroumis D., Bouropoulos N., and Fahr A. Physicochemical characterization of solid dispersions of three antiepileptic drugs prepared by solvent evaporation method. J. Pharm. Pharmacol. 59 (2007) 645-653
15. El-Badry M., and Fathy M. Properties of solid dispersions of piroxicam in pluronic F-98. J. Drug Del. Sci. Technol. 14 (2005) 199-205
16. El-Badry M., and Fathy M. Enhancement of the dissolution and permeation rates of meloxicam by formation of its freeze-dried solid dispersions in polvvinylpyrrilidone k-30. Drug Dev. Ind. Pharm. 32 (2006) 141-150
17. Etman M.A., and Nada A.H. Hydrotropic and cosolvent solubilisation of indomethacin. Acta Pharm. 49 (1999) 291-298
18. Fini A., Moyano J.R., Gines J.M., Perez-Martinez J.I., and Rabasco A.M. Diclofenac salts, II. Solid dispersions in PEG6000 and Gelucire 50/13. Eur. J. Pharm. Biopharm. 60 (2005) 99-111
19. Ford J.L., and Rubinstein M.H. Phase equilibria and dissolution rate of indomethacin-polyethylene glycol 6000 solid dispersions. Pharm. Acta Helv. 53 (1978) 93-98
20. Habib M.J., Akogyeram C., and Ahmadi B. Improved dissolution of indomethacin in coprecipitates with phosphorlipids. Part 1. Drug Dev. Ind. Pharm. 19 (1993) 499-505
21. Hancock B.C., and Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86 (1997) 1-12
22. Hirasawa N., Ishise S., Miyata H., and Danjo K. Physicochemical characterization and drug release studies of nilvadipine solid dispersions using water-insoluble polymer as a carrier. Drug Dev. Ind. Pharm. 29 (2003) 339-344
23. Jambhekar S., Casella R., and Maher T. The physicochemical characteristics and bioavailability of indomethacin from beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, and hydroxylpropyl-beta-cyclodextrin complexes. Int. J. Pharm. 270 (2004) 149-166
24. Khan N., and Craig D.Q.M. The influence of drug incorporation on the structure and release properties of solid dispersion in lipid matrices. J. Control. Release 93 (2003) 355-368
25. Krasowska H. Effect of micellar solubilization on the gastrointestinal absorption of indomethacin in the rate. Int. J. Pharm. 7 (1980) 137-143
26. Kreuter J. Feste dispersionen. In: Kereuter J., and Herzfeldt C.-D. (Eds). Grundlagen der arzneiformenlehre galenik vol. 2 (1999), Springer, Frankfurt am Main 262-274
27. Leuner C., and Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 50 (2000) 47-60
28. Lin C.W., and Cham T.M. Effect of particle size on the available surface area of nifedipine from nifedipine-polyethylene glycol 6000 solid dispersions. Int. J. Pharm. 127 (1996) 261-272
29. Liu C., and Desai K.G. Characteristics of rofecoxib-polyethylene glycol 4000 solid dispersions and tablets based on solid dispersions. Pharm. Dev. Technol. 10 (2005) 467-477
30. Lobenberg R., and Amidon G.L. Modern bioavailability, bioequivalence and biopharmaceutics classification system; new scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 50 (2000) 3-12
31. Nokhodchi A., Javadzadeh Y., Siahi-Shadbad M.R., and Barzegar-Jalali M. The effect of type and concentration of vehicles on the dissolution rate of poorly soluble drug (indomethacin) from liquisolid compacts. J. Pharm. Pharmac. Sci. 8 (2005) 18-25
32. Pan X., Julian T., and Augsburger L. Quantitative measurement of indomethacin crystallinity in indomethacin-silica gel binary system using differential scanning calorimetry and X-ray powder diffractometry. AAPS Pharm. Sci. Technol. 7 1 (2006). (Article 11)
33. Preechagoon D., Udomprateep A., and Manwiwa-ttanagul G. Improved dissolution rate of poorly soluble drug by incorporation of buffers. Drug Dev. Ind. Pharm. 26 (2000) 891-894
34. Sethia S., and Squillante E. Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. Int. J. Pharm. 272 (2004) 1-10
35. Sutananta W., Craig D.Q.M., and Newton J.M. The effects of ageing on the thermal behavior and mechanical properties of pharmaceutical glycerides. Int. J. Pharm. 111 (1994) 51-62
36. Sweetman S.C. Martindale: The Complete Drug Reference (2005), Pharmaceutical Press p. 47
37. Tantishaiyakul V., Kaewnopparat N., and Ingkata-wornwong S. Properties of solid dispersions of piroxicam in polyvinylpyrrolidne. Int. J. Pharm. Sci. 181 (1999) 143-151
38. Thybo P., Kristensen J., and Hovgaard L. Characterization and physical stability of tolfenamic acid-PVP K30 solid dispersions. Pharm. Dev. Technol. 12 (2007) 43-53
39. Urbanetz N.A., and Lippold B.C. Solid dispersions of nimodipine and polyethylene glycol 2000: dissolution properties and physico-chemical characterisation. Eur. J. Pharm. Biopharm. 59 (2005) 107-118
40. Valizadeh H., Nokhodchi A., Qarakhani N., Zakeri-Milani P., Azarmi S., Hassanzadeh D.L., and Löbenberg R. Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, Myrj 52, lactose, sorbitol, dextrin, and Eudragit E100. Drug Dev. Ind. Pharm. 30 (2004) 303-317
41. Wang X., de Armas H.N., Blaton N., Michoel A., and Van den Mooter G. Phase characterization of indomethacin in binary solid dispersions with PVP VA64 or Myrj 52. Int. J. Pharm. 345 (2007) 95-100